Cefoxitin Injection Rx
Generic Name and Formulations:
Cefoxitin sodium 1g, 2g; for IV inj; sodium content 2.3mEq/g.
Various generic manufacturers
Indications for Cefoxitin Injection:
Susceptible bacterial septicemia, lower respiratory or urinary tract, skin and skin structure, bone and joint, gynecologic, intraabdominal infections. Surgical prophylaxis.
Usually 1–2g every 6–8hrs. Uncomplicated: 1g every 6–8hrs. Moderately severe to severe: 1g every 4hrs or 2g every 6–8hrs. Max 2g every 4hrs or 3g every 6hrs. Prophylaxis: see literature.
<3months: not recommended. ≥3months: 80–160mg/kg per day in 4–6 equal divided doses; max 12g/day. Prophylaxis: see literature.
Penicillin or other allergy. Renal impairment (CrCl <50mL/min), reduce dose: see literature. GI disease (esp. colitis). Pregnancy (Cat.B). Nursing mothers.
Aminoglycosides may potentiate nephrotoxicity. Potentiated by probenecid. May cause false (+) Clinitest. May interfere with creatinine tests.
Local reactions, rash, pruritus, drug fever, GI upset, anaphylaxis, blood dyscrasias, elevated liver enzymes.
Formerly known under the brand name Mefoxin.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Clostridium Difficile Infection in Patients With Cancer — In the Clinic
- Targeted and Immunotherapies for Metastatic Renal Cell Carcinoma
- Nicotinamide and Cancer
- Atezolizumab, Carboplatin, Nab-Paclitaxel Combination Prolongs PFS in NSCLC
- FDA Approves Front-Line Brentuximab Vedotin Plus Chemotherapy for Hodgkin Lymphoma
- Opioid Prescription Protocol Decreases Opioid Use After Gynecologic Surgery
- Everolimus Plus Letrozole May Be Active in Recurrent Endometrial Carcinoma
- Affordable Care Act Increased Percentage of Insured Patients With Gynecologic Cancers
- Everolimus Plus Letrozole: An Effective First-Line Therapy for Advanced Breast Cancer
- FDA Approves Nilotinib for Pediatric Patients With CML